Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Trial Profile

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs CAEL 101 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 12 Dec 2017 Results of the final analysis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Dec 2017 Results presented in a Fortress Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top